Direkt zum Inhalt
Merck
  • Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.

Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.

Oncotarget (2015-04-15)
Séverine Roselli, Jay Pundavela, Yohann Demont, Sam Faulkner, Sheridan Keene, John Attia, Chen Chen Jiang, Xu Dong Zhang, Marjorie M Walker, Hubert Hondermarck
ZUSAMMENFASSUNG

The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed by immunohistochemistry in a series of 318 clinically annotated breast cancers and 53 normal breast tissues. Sortilin was detected in epithelial cells, with increased levels in cancers, as compared to normal tissues (p = 0.0088). It was found in 79% of invasive ductal carcinomas and 54% of invasive lobular carcinomas (p < 0.0001). There was an association between sortilin expression and lymph node involvement (p = 0.0093), suggesting a relationship with metastatic potential. In cell culture, sortilin levels were higher in cancer cell lines compared to non-tumorigenic breast epithelial cells and siRNA knockdown of sortilin inhibited cancer cell adhesion, while proliferation and apoptosis were not affected. Breast cancer cell migration and invasion were also inhibited by sortilin knockdown, with a decrease in focal adhesion kinase and SRC phosphorylation. In conclusion, sortilin participates in breast tumor aggressiveness and may constitute a new therapeutic target against tumor cell invasion.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Propidiumjodid, ≥94.0% (HPLC)
Sigma-Aldrich
Anti-Aktin, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
Propidiumjodid -Lösung
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Sort1
Sigma-Aldrich
MISSION® esiRNA, targeting human SORT1